Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$0.21 - $0.43 $228,255 - $467,380
-1,086,932 Reduced 12.65%
7,505,539 $1.65 Million
Q2 2023

Aug 14, 2023

BUY
$0.55 - $1.26 $310,716 - $711,823
564,939 Added 7.04%
8,592,471 $6.01 Million
Q1 2023

May 15, 2023

BUY
$0.89 - $2.52 $2.3 Million - $6.51 Million
2,582,776 Added 47.44%
8,027,532 $7.22 Million
Q4 2022

Feb 14, 2023

SELL
$1.02 - $7.48 $2.68 Million - $19.7 Million
-2,629,541 Reduced 32.57%
5,444,756 $6.42 Million
Q3 2022

Nov 14, 2022

BUY
$6.04 - $9.66 $2.41 Million - $3.85 Million
398,720 Added 5.19%
8,074,297 $60.8 Million
Q2 2022

Aug 15, 2022

BUY
$4.99 - $8.96 $900,764 - $1.62 Million
180,514 Added 2.41%
7,675,577 $48.4 Million
Q1 2022

May 16, 2022

BUY
$3.84 - $9.74 $1.73 Million - $4.39 Million
450,329 Added 6.39%
7,495,063 $62.2 Million
Q4 2021

Feb 14, 2022

BUY
$5.12 - $8.19 $5.81 Million - $9.3 Million
1,135,073 Added 19.21%
7,044,734 $36.6 Million
Q3 2021

Nov 15, 2021

BUY
$6.68 - $9.1 $2.64 Million - $3.59 Million
394,630 Added 7.16%
5,909,661 $39.5 Million
Q2 2021

Aug 16, 2021

BUY
$7.82 - $9.23 $8.33 Million - $9.83 Million
1,064,790 Added 23.93%
5,515,031 $47 Million
Q1 2021

May 17, 2021

BUY
$8.44 - $12.66 $4.46 Million - $6.69 Million
528,406 Added 13.47%
4,450,241 $39.4 Million
Q4 2020

Feb 12, 2021

BUY
$7.98 - $12.29 $20.2 Million - $31.1 Million
2,529,780 Added 181.73%
3,921,835 $48.2 Million
Q3 2020

Nov 16, 2020

BUY
$7.96 - $12.42 $11.1 Million - $17.3 Million
1,392,055 New
1,392,055 $11.3 Million

Others Institutions Holding EIGR

About Eiger BioPharmaceuticals, Inc.


  • Ticker EIGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,966,800
  • Market Cap $556M
  • Description
  • Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...
More about EIGR
Track This Portfolio

Track Ameriprise Financial Inc Portfolio

Follow Ameriprise Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.